Last reviewed · How we verify
NCT03426150
Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks
Phase 4 trial testing CPP-ACP in Dental Erosion in 12 participants. Completed in 5 February 2018.
25 October 2017
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 12 |
| Start date | 25 December 2015 |
| Primary completion | 25 October 2017 |
| Estimated completion | 5 February 2018 |
Drugs / interventions tested
Conditions studied
- Dental Erosion — all drugs for Dental Erosion →
Sponsor
Fujian Medical University
Who can join
Adults 18 to 60, any sex, with Dental Erosion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
40 specimens were prepared from fresh-extracted human molars and further embedded using the acrylic resin. Specimens were randomly divided into 2 groups according to the treatment before in vivo erosion (n=20): CPP-ACP for 3 min (CPP-ACP group) and deionized water for 3 min (control group). 10 healthy volunteers were recruited and customized maxillary appliance containing 4 specimens (2 from CPP-ACP group and 2 from control group) was fabricated for each volunteer. Participants were instructed to drink 150 ml cola in 5 min using the gargling method after placing appliances intraorally for 2 h. The in vivo attacks were performed 4 X 5 min with 1-h interval daily over 7 d. The surface microhardness and surface microstructure of the specimens were evaluated at the baseline and after the treatment. The data were statistically analyzed using three-way ANOVA and post hoc tests. Data were considered statistically significant at a level of P \<0.05.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
In situ effect of Tooth Mousse containing CPP-ACP on human enamel subjected to in vivo acid attacks.
Yu H, Jiang NW, Ye XY, Zheng HY, et al · · 2018 · cited 26× · PMID 29857075 · DOI 10.1016/j.jdent.2018.05.021
Verify or expand the search:
- PubMed search for NCT03426150
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CPP-ACP
Trials testing the same drug.
- NCT04401280 — Bioactive Glass in the Treatment of Enamel White Spot Lesions · Phase 3 · completed
- NCT03973554 — Caries Prevention Potential of Pearl Powder Versus CPP-ACP on Enamel White Spot Lesions · Phase 2 · unknown
- NCT03865680 — Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in · Phase 2 · completed
- NCT04112706 — Efficacy of CPP-ACP on Bleaching Related Sensitivity · NA · completed
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03426150 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 8 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03426150.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing